The present invention relates to the field of medicine, and particularly relates to a water-soluble allopregnenolone (3,5-tetrahydroprogesterone) derivative, a pharmaceutical composition comprising the same, and use thereof in prevention or treatment of central nervous system diseases, in sedation and hypnosis, in treatment of Alzheimer's disease, in treatment of epilepsy or in treatment of depression, especially postpartum depression.

##STR00001##

A compound represented by the following general formula (I):

##STR00001##

(the symbols in the general formula (I) are as described in the Description), wherein the compound contains one or more structures selected from the following (i) and (ii): (i) A is an aliphatic hydrocarbon group containing two or more alicyclic hydrocarbon groups, containing a saturated aliphatic hydrocarbon group at a terminal position directly bound to N, and optionally containing O, S, N in a carbon chain (ii) at least one of R.sup.2, R.sup.3, R.sup.4 and R.sup.5 is a cycloalkyl group optionally containing a substituent group or an aryl group optionally containing a substituent group.

A compound represented by the following general formula (I):

##STR00001##

(the symbols in the general formula (I) are as described in the Description), wherein the compound contains one or more structures selected from the following (i) and (ii): (i) A is an aliphatic hydrocarbon group containing two or more alicyclic hydrocarbon groups, containing a saturated aliphatic hydrocarbon group at a terminal position directly bound to N, and optionally containing O, S, N in a carbon chain (ii) at least one of R.sup.2, R.sup.3, R.sup.4 and R.sup.5 is a cycloalkyl group optionally containing a substituent group or an aryl group optionally containing a substituent group.

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, attention deficit hyperactivity disorder, fibromyalgia, irritable bowel syndrome, and/or premature ejaculation are described. ##STR00001##

Chemical syntheses and medical uses of novel inhibitors of the uptake of monoamine neurotransmitters and pharmaceutically acceptable salts and prodrugs thereof, for the treatment and/or management of psychotropic disorders, anxiety disorder, generalized anxiety disorder, depression, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, hot flashes, senile dementia, migraine, hepatopulmonary syndrome, chronic pain, nociceptive pain, neuropathic pain, painful diabetic retinopathy, bipolar depression, obstructive sleep apnea, psychiatric disorders, premenstrual dysphoric disorder, social phobia, social anxiety disorder, urinary incontinence, anorexia, bulimia nervosa, obesity, ischemia, head injury, calcium overload in brain cells, drug dependence, attention deficit hyperactivity disorder, fibromyalgia, irritable bowel syndrome, and/or premature ejaculation are described. ##STR00001##

The invention relates to a process for preparing triaryl organoborates proceeding from organoboronic esters in the presence of an n-valent cation 1/n K.sup.n+, comprising the anhydrous workup of the reaction mixture and the use of the triaryl organoborates obtained as co-initiator in photopolymer formulations, holographic media and holograms.

The invention relates to a process for preparing triaryl organoborates proceeding from organoboronic esters in the presence of an n-valent cation 1/n K.sup.n+, comprising the anhydrous workup of the reaction mixture and the use of the triaryl organoborates obtained as co-initiator in photopolymer formulations, holographic media and holograms.

A compound represented by specific chemical formula, a core including the same, a core-shell dye including a shell surrounding the core, a photosensitive resin composition including the same, and a color filter manufactured using the photosensitive resin composition are disclosed.

The invention provides branched trialkylamine oxides with improved properties. The trialkylamine oxides of the invention produced from branched trialkylamines, in one embodiment, can be made using certain branched C10-12 enals and aldehydes. The invention also provides an trialkylamine oxide having the formula:

##STR00001##

wherein R5, R6 and R7 are independently at least one of C3H7, C2H5, CH3, or H, or mixtures thereof; and wherein R5 and R6 are not H at the same time. In one embodiment, the trialkylamine oxides of the invention can be useful in making various products, for example, as surfactants.

The invention provides branched hydrophobes for the production of surfactants with improved properties over linear hydrophobes. The invention also provides branched C10-12 enals and aldehydes that are oxidized to branched fatty acids or hydrogenated to branched fatty alcohols and further derivatized to surfactants, through ethoxylation or esterification and other or subsequent reactions. The invention further provides surfactants made from the branched trialkylamine intermediates, including amphoteric, cationic and nonionic surfactants.